Supplemental figure 1



Supplemental figure 1. Conformational analysis of soluble KIR-Fc recombinant proteins. All recombinant proteins used in this study were checked for conformational folding using DX9 and Z27 conformation-specific antibodies. Displayed are the dot plot analyses for the mock supernatant (A), KIR3DL1*001 (B), KIR3DL1*009 (C), KIR3DL1*005 (D), KIR3DL1*042 (E), KIR3DL1*001 I47V (F), KIR3DL1*001 S58G (G), KIR3DL1*001 V92M (H), KIR3DL1*001 I47V, S58G (I), KIR3DL1*001 I47V, V92M (J), KIR3DL1*001 S58G, V92M (K), KIR3DL1*005 L283W (L), KIR3DS1*013 (M). N, Dot plot of the protein A microscpheres incubated with the supernatant of a mock transfection followed by staining with DX9 and a PE-conjugated antibody specific for human IgG. O, Staining of the microspheres pre-incubated with KIR3DL1*001-Fc at

4°C. P, Staining of KIR3DL1*001-Fc protein following incubation of the protein at 70°C for two minutes. Q, Staining of native KIR3DL1*001-Fc (dashed line) or heat denatured KIR3DL1*001-Fc (solid line) with PE conjugated Z27. Incubation of the microspheres with mock supernatant was used as the control (solid grey).

Supplemental figure 2



Supplemental figure 2. Soluble KIR-Fc binding to HLA-B*44:03. Recombinant KIR3DL1*001 (A), KIR3DL1*005 (B), KIR3DL1*009 (C), and KIR3DL1*042 (D) were bound to HLA-B*44:03 on the surface of 721.221 cells in the presence of DX9 or Z27 (4 μg/ml). The background binding of soluble KIR3DL1*001 to the parental 721.221 cells was used as the control. E, The binding of wild-type KIR3DL1*001 and KIR3DL1*005 to HLA-B*44:03 positive cells was compared to binding of the mutant KIR3DL1*005 L283W. The results were analyzed using a one-way ANOVA followed

by a Tukey's multiple comparisons test (vs 3DL1*005, *** $P < 0.001$).